-
An analysis of the effect of daily estrogen-progestin administration to postmenopausal women was summarized on the Internet site of the New England Journal of Medicine on March 17. The authors' message suggests that postmenopausal hormone therapy should be used only as brief treatment for severe menopausal symptoms.
-
One of the benefits that has come from the release of the data from the Prempro® arm of the Womens Health Initiative (WHI) on July 9, 2002, has been a re-evaluation of the pros and cons of menopausal hormonal therapy. In undertaking this appraisal, one inevitably asks what are rational alternatives to hormone use.
-
Women with advanced epithelial ovarian cancer did not describe the treatment decision-making process as shared; rather, they described an interaction that was directed by their physician.
-
Postmenopausal estrogen-progestin therapy increased the risk of breast cancer in a population-based cohort in Sweden, and estrogen-only did not.
-
Only tamoxifen has enough evidence to recommend it for the prevention of breast cancer, and its use is limited to very high-risk women with a low risk of side effects.
-
Magnesium sulfate is more effective than nimodipine for prophylaxis against seizures in women with severe preeclampsia.
-
-
Radical trachelectomy combined with pelvic lymphadenectomy can be a feasible method of treatment for early-stage cervical cancer in women who want to preserve their fertility.
-
In postmenopausal patients with sexual dysfunction, it is still unclear which, if any, therapy is indicated.
-
The trial concluded that platinum-based adjuvant chemotherapy improved overall survival and recurrence-free survival at 5 years in this combined group of patients with early stage ovarian cancer defined by the inclusion criteria of the ICON1 and ACTION trials.